Multicenter, Open-label, Randomized Phase 2 Study of Weekly versus Alternative Ficerafusp Alfa Dosing in Combination with Pembrolizumab for First-line Recurrent or Metastatic HNSCC
Sponsor: Bicara Therapeutics Inc.
Phase: 2
Disease: Head and neck squamous cell carcinoma, Recurrent or metastatic oropharyngeal squamous cell carcinoma, Recurrent or metastatic oral cavity squamous cell carcinoma, Recurrent or metastatic laryngeal and hypopharyngeal squamous cell carcinoma
EU trial number: 2026-526741-10-00
Population: Adults with recurrent or metastatic squamous cell carcinoma of oral cavity, larynx, hypopharynx, or HPV-negative oropharynx, eligible for first-line pembrolizumab monotherapy with tumor PD-L1 CPS ≥1 and no systemic therapy for recurrent/metastatic disease.
Register Investigator Interest
Interested in offering this trial to suitable patients?